How to Help Your Patients Save Money on Skyrizi: A Provider's Guide to Savings Programs

At a list price of approximately $22,383 per dose, Skyrizi is one of the most expensive medications you can prescribe. For patients who don't have adequate insurance coverage or who are caught in the prior authorization process, that price tag can mean delayed or abandoned treatment. As a provider, you play a critical role in connecting patients to the savings resources that can make Skyrizi accessible. This guide covers every savings program available in 2026 and the workflows to activate them efficiently.

Understanding the Skyrizi Cost Landscape

Before discussing savings programs, it's helpful to understand how Skyrizi costs flow through the healthcare system:

List price (WAC): ~$22,383 per dose (January 2025 data from AbbVie)

Annual gross cost (psoriasis/PsA): ~$90,000+ for maintenance at 4–5 doses/year (every 12 weeks)

Formulary tier: Specialty tier (Tier 4–5 on most commercial plans); requires prior authorization

Medicare coverage: Part B (physician-administered IV doses) or Part D (self-injected maintenance doses); no manufacturer co-pay card available for Medicare beneficiaries

Program 1: Skyrizi Complete Savings Card (Commercial Insurance)

For commercially insured patients, the Skyrizi Complete Savings Card is the most impactful savings tool available. Eligible patients may pay as little as $0 per quarterly dose. Key details for providers:

Enrollment: Call 1-866-SKYRIZI or submit the Skyrizi Complete Enrollment Form — your staff can enroll patients at the time of prescribing

Eligibility: Commercially insured patients meeting AbbVie criteria; not available for Medicare, Medicaid, TRICARE, or VA beneficiaries

Coverage includes: Skyrizi drug costs, associated infusion costs for IBD patients, and eligible lab test costs (up to $1,000/year for labs)

Important caveat: Patients whose plans use copay accumulators or copay maximizer programs may have limited savings card benefits. Savings limits can range from $4,000 to $14,000 annually in these cases

Program 2: AbbVie Bridge Program (Insurance Delays or Denials)

AbbVie's bridge program through Skyrizi Complete is specifically designed for patients who experience insurance coverage delays or denials. As a provider, you should initiate this program simultaneously with the PA process—not as an afterthought when a denial arrives.

Trigger conditions: 5+ business day delay in medical benefit approval, or denial of PA request

Eligibility: Commercially insured patients ≤63 years old with a valid Skyrizi prescription and a PA denial with confirmed appeal on file

Duration: Up to 2 years or until insurance coverage is approved, whichever is earlier

Not available for Medicare, Medicaid, or TRICARE beneficiaries

Continued eligibility requires submission of a PA appeal every 180 days

Program 3: myAbbVie Assist (Uninsured or Underinsured Patients)

For patients without insurance or with inadequate coverage, the myAbbVie Assist Patient Assistance Program can provide Skyrizi at no cost to qualifying patients. In 2024, AbbVie assisted more than 235,000 patients through its assistance programs.

How to initiate myAbbVie Assist from your office:

Download the patient assistance application from AbbVie.com/PatientAccessSupport

Complete the Healthcare Provider section and have the provider sign and date the form

Patient completes their portion with income documentation (federal tax return, pay stubs, or W-2)

Fax the completed application to 1-866-250-2803 or mail to AbbVie Patient Access Support, North Chicago, IL 60064

Program 4: Patient Access Network (PAN) Foundation (Medicare Patients)

For Medicare beneficiaries who have significant out-of-pocket costs for Skyrizi, the Patient Access Network (PAN) Foundation's Inflammatory Bowel Disease fund provides grants up to $4,000 annually. Eligibility is income-based. Contact PAN at panfoundation.org or 1-866-316-7263. Note: Fund availability varies and there may be wait lists at certain times.

Leveraging Skyrizi Complete Field Reimbursement Managers

Skyrizi Complete provides Field Reimbursement Managers (FRMs) who are trained in payer-specific coverage policies and can support your office directly. FRMs can:

Identify which savings programs each patient qualifies for based on their insurance

Educate your staff on payer-specific PA requirements to reduce first-time denial rates

Assist with the appeals process and peer-to-peer review scheduling

Connect patients with the appropriate Skyrizi Complete savings resource for their coverage type

Quick Reference: Which Program for Which Patient?

Commercial insurance, PA approved: Skyrizi Complete Savings Card → as little as $0/dose

Commercial insurance, PA delayed/denied: AbbVie bridge program → Skyrizi at no charge for eligible patients during appeals (up to 2 years)

Uninsured or underinsured: myAbbVie Assist → free medication for qualifying patients

Medicare patients with high out-of-pocket costs: PAN Foundation IBD fund → up to $4,000/year (subject to fund availability)

For your patients who have overcome financial barriers but still need help locating their prescription, medfinder for providers can help them find which specialty pharmacies can fill their Skyrizi prescription—saving time for your office and frustration for your patients.

For a full overview of access barriers beyond cost—including PA and step therapy strategies—see Skyrizi Shortage: What Providers and Prescribers Need to Know in 2026.